Clinical Trials
5
Active:3
Completed:2
Trial Phases
1 Phases
Phase 3:4
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 3
4 (100.0%)The Evaluation of Injection Site Pain and Adherence in Patients Switching from a Low to High Concentration Adalimumab (AVT-02) Across Multiple Indications.
Active, not recruiting
- Conditions
- Crohn DiseaseAnkylosing SpondylitisPlaque PsoriasisHidradenitis SuppurativaUlcerative ColitisPsoriatic ArthritisRheumatoid Arthritis
- Interventions
- Biological: AVT02 (Alvotech Biosimilar to Adalimumab)
- First Posted Date
- 2023-06-22
- Last Posted Date
- 2025-02-20
- Lead Sponsor
- Jamp Pharma Corporation
- Target Recruit Count
- 600
- Registration Number
- NCT05913817
- Locations
- 🇨🇦
JAMP Pharma Corporation, Montréal, Quebec, Canada
News
No news found